Clinical Trials Logo

Clinical Trial Summary

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. The prognosis of HCC remains poor, with a 5-year survival rate of 18%. Risk factors for HCC include viral infection, autoimmune hepatitis, chronic alcohol use or metabolic fatty liver disease, obesity, and diabetes mellitus.


Clinical Trial Description

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. The prognosis of HCC remains poor, with a 5-year survival rate of 18%. Risk factors for HCC include viral infection, autoimmune hepatitis, chronic alcohol use or metabolic fatty liver disease, obesity, and diabetes mellitus. Furthermore, alterations and chronic inflammation of the microenvironment can facilitate the transformation of normal liver stem cells into precancerous tumor stem cells. All these underlying pathogenic stimuli can induce a spectrum of genetic and epigenetic modifications, which are involved in the cell cycle, cell growth and regulation of adhesion. Therefore, heterogeneity and tumor priming potential arise from a combination of both endogenous and exogenous factors. However, current in vitro models, based on conventional hepatoma and hepatocarcinoma cell lines, fail to recapitulate key characteristics of tumor tissue such as three-dimensional tissue architecture, cellular heterogeneity, and cell-cell interactions. Organoids, which are 3D cellular structures generated from induced pluripotent stem cells and adult tissue-resident stem cells, have recently been exploited to overcome the limitations of 2D cell culture systems, emerging as powerful tools for studying human diseases. Therefore, organoid structures stably preserve the genetic information of autologous tissue by mimicking the pathological state of the tissue itself. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06311396
Study type Interventional
Source Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Contact Luca Vittorio Carlo Valenti
Phone 02 5503 6595
Email luca.valenti@policlinico.mi.it
Status Recruiting
Phase N/A
Start date January 1, 2021
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT03253250 - The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection Phase 4
Terminated NCT01760616 - Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy Phase 4
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Not yet recruiting NCT03149523 - Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors N/A
Recruiting NCT05009550 - ESP Block on Patient Outcomes in Patients With Liver Tumor Undergoing Radiofrequency Ablation N/A
Recruiting NCT06342414 - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Recruiting NCT03132740 - Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
Completed NCT03164382 - Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma Phase 3
Completed NCT03572582 - Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma Phase 2
Completed NCT04266548 - Arterial Base Fluorescence Segmental Positive Staining N/A
Recruiting NCT03013712 - A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer Phase 1/Phase 2
Recruiting NCT01350726 - Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan N/A
Completed NCT06245798 - Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Recruiting NCT04220944 - Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. Phase 1
Completed NCT02332551 - Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder N/A
Completed NCT02352935 - Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function N/A
Completed NCT02834780 - Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma Phase 1
Not yet recruiting NCT06182865 - A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy N/A
Completed NCT05007548 - to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve Phase 2
Completed NCT03163186 - Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial). N/A